Duloxetine, Pregabalin, and Amitriptyline for Fibromyalgia: A Side-by-Side Comparison

Three medications stand above the rest in fibromyalgia pharmacotherapy: duloxetine, pregabalin, and amitriptyline. Other drugs are used (milnacipran has FDA approval in the US; gabapentin is used off-label), but these three have the most extensive evidence and the widest clinical use. Each works through a different mechanism, has a different side-effect profile, and helps a different subset of patients. None is a cure. Understanding what each does, and what it does not do, is necessary for realistic expectations [6].

It is also worth acknowledging at the outset that the effect sizes for all three are modest. These medications help a meaningful proportion of patients achieve a meaningful reduction in symptoms, but they do not eliminate fibromyalgia. The research consistently shows that the best outcomes come from combining medication with exercise, sleep management, and pain neuroscience education, not from medication alone [5].

The Mechanisms

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the availability of serotonin and norepinephrine in the synaptic cleft, which boosts the function of descending pain inhibition pathways, the brainstem circuits that normally dampen pain signals at the spinal cord level. In fibromyalgia, these pathways are underactive; the system that should be turning the volume down on pain signals is not doing its job effectively. Duloxetine turns the volume down on pain by strengthening the system that was supposed to be doing that already [6].

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels on presynaptic neurons in the spinal cord. This reduces the release of excitatory neurotransmitters (glutamate, substance P) at spinal cord synapses. Where duloxetine boosts the inhibitory side, pregabalin reduces the excitatory side. The amplified signaling characteristic of central sensitization is dampened at its source [6]. The two drugs are, in a sense, complementary: one strengthens the brakes, the other eases off the accelerator.

Amitriptyline is a tricyclic antidepressant with multiple mechanisms: it inhibits serotonin and norepinephrine reuptake (like duloxetine, though less selectively), blocks sodium channels, and has anticholinergic and antihistaminic properties. The sodium channel blockade may contribute to pain relief independently of the monoamine effects. The antihistaminic effects produce the sedation that makes amitriptyline useful for sleep. At the low doses used for fibromyalgia (10-50 mg), the antidepressant effect is minimal; the analgesic and sleep effects are the primary targets. This pharmacological breadth is both the drug’s strength and its complexity: it does several things at once, which is useful when the patient has several symptoms, but it also means the side-effect profile reflects all of those mechanisms simultaneously.

The Evidence

Häuser and colleagues conducted a comprehensive meta-analysis comparing drug classes for fibromyalgia [1]. The findings:

Duloxetine at 60-120 mg daily: the Cochrane review found an NNT of approximately 8 for achieving a 30% or greater pain reduction (moderate-quality evidence) [2]. That NNT means roughly one in eight patients will experience a meaningful improvement attributable to the drug rather than placebo. Duloxetine also improves mood, which is relevant for the approximately 30-50% of fibromyalgia patients with comorbid depression or anxiety. The effect on physical function is small to moderate. The placebo response in fibromyalgia trials is itself substantial, typically around 30%, which means the absolute proportion of patients who improve on duloxetine is higher than the NNT suggests; the drug-specific contribution is what the NNT captures.

Pregabalin at 300-450 mg daily: the Cochrane review found an NNT of approximately 9 for achieving a 50% or greater pain reduction at the 450 mg dose [3]. Note that this is a higher bar than the duloxetine figure (50% reduction rather than 30%), which makes the two NNTs not directly comparable. Pregabalin also improves sleep quality, which is relevant given the high prevalence of sleep disruption in fibromyalgia. The effect on fatigue is less consistent. For patients whose primary complaint is pain accompanied by severely disrupted sleep, pregabalin’s dual benefit on both domains is a practical advantage.

Amitriptyline at 25-50 mg at bedtime: the Cochrane review concluded that the evidence was of low quality, not because the drug does not work but because the trials were older, smaller, and less rigorously designed than the duloxetine and pregabalin trials [4]. Despite this, amitriptyline has been used for fibromyalgia for decades with consistent clinical reports of benefit, and the EULAR guidelines recommend it as first-line because of its broad effects on pain, sleep, and function at low cost [5]. The discrepancy between the formal evidence grade and clinical experience reflects the history of the drug: it was in widespread use for fibromyalgia before the era of large, industry-funded trials, and no manufacturer has an incentive to fund rigorous modern trials of a generic drug.

Side Effects Compared

The side-effect profiles differ meaningfully, and this often drives the choice between medications.

Duloxetine: Nausea (most common, usually resolves within 2 weeks), dry mouth, constipation, dizziness, and sexual dysfunction. Discontinuation syndrome (dizziness, nausea, irritability) on abrupt withdrawal is significant and requires gradual tapering. Approximately 15-20% of trial participants discontinued due to side effects. The nausea is most pronounced in the first week and can be mitigated by starting at a lower dose and titrating up, though this extends the time to therapeutic effect.

Pregabalin: Dizziness (30-40% at 450 mg), somnolence (20-25%), weight gain (10-15%), and peripheral edema (6-10%). The cognitive effects (mental fog, word-finding difficulty) can overlap uncomfortably with fibromyalgia’s own cognitive symptoms, making it difficult for some patients to distinguish drug side effects from disease symptoms. Approximately 20-25% discontinued due to side effects at 450 mg. Pregabalin is a Schedule V controlled substance in the US.

Amitriptyline: Morning sedation (the bedtime dosing exploits the sedation for sleep, but it can extend into the morning), dry mouth, constipation, weight gain, and urinary retention. At the low doses used for fibromyalgia, the cardiac conduction effects that limit tricyclics at antidepressant doses are minimal but warrant caution in patients with existing cardiac conditions. The advantage is that the sedation can be therapeutic: for patients whose sleep disruption is a primary driver of their symptoms, the sedative properties are a feature rather than a side effect.

Choosing Between Them

No head-to-head trial has compared all three drugs directly, so the choice is based on clinical reasoning rather than comparative data [6]:

When pain with comorbid depression or anxiety is the primary concern, duloxetine has the most evidence for both. Its effect on mood is independent of its analgesic effect, which means it addresses two common problems with one medication.

When pain with significant sleep disruption dominates, pregabalin or amitriptyline may be preferred, with amitriptyline offering the stronger sedative effect. If sleep is the primary driver and the patient tolerates sedation well, amitriptyline is often the more practical choice.

When cost is a consideration, amitriptyline is generic and inexpensive. Duloxetine is also now available generically. Pregabalin is available generically in most markets.

When a first trial fails, switching to a drug from a different mechanism class is logical. Duloxetine and pregabalin work through different mechanisms, so failure on one does not predict failure on the other. This is one of the practical advantages of having three drugs that each work differently: a patient who does not respond to one still has two mechanistically distinct alternatives.

Realistic Expectations

The conversation about medication in fibromyalgia often gets framed as “which drug works best,” but the more accurate framing is “which drug helps which patients with which symptoms, and to what degree.” The trial data consistently shows that approximately one-third of patients respond meaningfully to any given medication, another third has partial benefit, and the remaining third does not respond or cannot tolerate the side effects [1].

This is not a failure of the medications. It reflects the heterogeneity of fibromyalgia: not all patients have the same balance of deficient descending inhibition and excessive excitatory signaling, and a drug targeting one mechanism will not help a patient whose dominant driver is the other. The empirical nature of treatment selection, trying one and switching if it does not work, is not a shortcoming of the field; it is an accurate reflection of current biological understanding.

It is also worth noting that medication in fibromyalgia is rarely the whole treatment. The best outcomes in clinical practice tend to come from combining medication with exercise, sleep management, and in some cases pain neuroscience education. Medication addresses one set of mechanisms; the others require different interventions. The question is not just which drug to try first, but what combination of approaches addresses the full scope of the patient’s symptoms.

What Remains Uncertain

Whether combining duloxetine and pregabalin produces meaningfully better outcomes than either alone has not been answered by a large, well-designed trial. Which patients will respond to which medication cannot currently be predicted before starting treatment; treatment remains empirical, and many patients try two or three medications before finding one that helps. How long medication should be continued once effective is not addressed by the trial evidence, which rarely extends beyond a year. And whether newer drug targets (low-dose naltrexone, cannabis-based therapies, glutamate receptor modulators) will eventually outperform these three is a question that current evidence cannot answer, though interest is high and trials are ongoing.

Getting support for chronic pain. Chronic pain, including fibromyalgia, is a complex medical condition that deserves proper clinical attention. A GP, rheumatologist or pain specialist can help develop a management plan. The American Chronic Pain Association (theacpa.org) and the National Fibromyalgia Association (fmaware.org) have patient resources and practitioner directories.